Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 1;41(6):540-548.
doi: 10.3343/alm.2021.41.6.540.

Biomarkers for Prognosis and Treatment Response in COVID-19 Patients

Giulia Bivona  1 , Luisa Agnello  1 , Marcello Ciaccio  1   2
Affiliations
Review

Biomarkers for Prognosis and Treatment Response in COVID-19 Patients

Giulia Bivona et al. Ann Lab Med. .

Abstract

During a severe infection such as coronavirus disease 2019 (COVID-19), the level of almost all analytes can change, presenting a correlation with disease severity and survival; however, a biomarker cannot be translated into clinical practice for treatment guidance until it is proven to have a significant impact. Several studies have documented the association between COVID-19 severity and circulating levels of C-reactive protein (CRP) and interleukin-6, and the accuracy of the CRP level in predicting treatment responses has been evaluated. Moreover, promising findings on prothrombin and D-dimer have been reported. However, the clinical usefulness of these biomarkers in COVID-19 is far from proven. The burst of data generation during this pandemic has led to the publication of numerous studies with several notable drawbacks, weakening the strength of their findings. We provide an overview of the key findings of studies on biomarkers for the prognosis and treatment response in COVID-19 patients. We also highlight the main drawbacks of these studies that have limited the clinical use of these biomarkers.

Keywords: Biomarkers; COVID-19; Coronavirus; Predictive value; Severity.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

None declared.

Figures

Fig. 1
Fig. 1
Alterations induced by SARS-CoV-2 infection. Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.
See this image and copyright information in PMC

References

    1. Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferrari M, et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC task force evaluation of the latest evidence. Clin Chem Lab Med. 2020;58:1037–52. doi: 10.1515/cclm-2020-0722. - DOI - PubMed
    1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–7. doi: 10.1111/jth.14768. - DOI - PMC - PubMed
    1. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9:727–32. doi: 10.1080/22221751.2020.1746199. - DOI - PMC - PubMed
    1. Guterres A, de Azeredo Lima CH, Miranda RL, Gadelha MR. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19? Infect Genet Evol. 2020;85:104417. doi: 10.1016/j.meegid.2020.104417. - DOI - PMC - PubMed
    1. Chauhan N, Jaggi M, Chauhan SC, Yallapu MM. COVID-19: fighting the invisible enemy with microRNAs. Expert Rev Anti Infect Ther. 2021;19:137–45. doi: 10.1080/14787210.2020.1812385. - DOI - PMC - PubMed